(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
14 April 2022 (14.04.2022)

WIPO | PCT

(10) International Publication Number
WO 2022/076662 A1

(51) International Patent Classification:
C07D 311/30 (2006.01) *C07D 417/12* (2006.01)
C07D 401/12 (2006.01) *C07D 417/14* (2006.01)
C07D 401/14 (2006.01) *C07D 471/04* (2006.01)
C07D 403/12 (2006.01) *A61K 31/352* (2006.01)
C07D 403/14 (2006.01) *A61K 31/4709* (2006.01)
C07D 405/12 (2006.01) *A61K 31/517* (2006.01)
C07D 405/14 (2006.01) *A61P 35/00* (2006.01)
C07D 413/14 (2006.01)

(21) International Application Number:
PCT/US2021/053936

(22) International Filing Date:
07 October 2021 (07.10.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/088,778 07 October 2020 (07.10.2020) US

(71) Applicant: **ATHENEX, INC.** [US/US]; 1001 Main Street, Suite 600, Buffalo, New York 14203 (US).

(72) Inventors: **URGAONKAR, Sameer**; 27 Bridgehampton Circle, Williamsville, New York 14221 (US). **SAID, Ahmed M.**; 1260 North Forest Road, L8, Williamsville, New York 14221 (US). **NASIEF ABDEL SAYED, Nader N.**; 34 Jenawood Lane, Amherst, New York 14221 (US). **PITZONKA, Laura Beth**; 5115 Olympic Avenue, Blasdell, New York 14219 (US). **CUTLER, Murray John**; 31 John Stiver Crescent, Markham, Ontario L3R 9A9 (CA). **SMOLINSKI, Michael P.**; 92 Newgate Road, Amherst, New York 14226 (US). **LAU, Johnson Yiu-Nam**; 6230 Cedar Creek Drive, Houston, Texas 77057 (US).


(74) Agent: **ERLACHER, Heidi** et al.; Cooley LLP, 1299 Pennsylvania Avenue, Suite 700, Washington, District of Columbia 20004 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

(54) Title: ACETAMIDO-PHENYLBENZAMIDE DERIVATIVES AND METHODS OF USING THE SAME



(I)

(57) Abstract: The present disclosure relates to compounds of Formula (I); and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for the treatment of disorders in which expression of P-glycoprotein and/or cytochrome P450 (*e.g.*, CYP3A4) is modulated (e.g., cancers which have developed multi-drug resistance).

[Continued on next page]

WO 2022/076662 A1

Published:
— *with international search report (Art. 21(3))*